Skip to main content

Share story

Security

When Reality Diverges from the Playbook: Darktrace Identifies Encryption in a World Leaks Ransomware Attack

When Reality Diverges from the Playbook: Darktrace Identifies Encryption in a World Leaks Ransomware Attack Image: Primary
Darktrace detected the presence of ransomware and data encryption linked to World Leaks in January 2026. The incident occurred in the network of a healthcare sector organization. The attack involved both exfiltration of customer data and subsequent encryption, which contradicted reports that the group had pivoted to eliminating encryption from its operations. Investigations revealed that threat actors likely gained initial access via a Fortigate appliance in mid-October. The three-month dwell time allowed the use of living off the land techniques for lateral movement, including PsExec. Command and control communications were established using Cloudflare Tunnel. A significant volume of data was exfiltrated to the MEGA cloud storage platform. Encryption of customer data followed. Darktrace's Autonomous Response capability was active and initially blocked suspicious connectivity, buying time for the customer to remediate, although the attack continued once the mitigative actions expired.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Darktrace, HIPAA Journal, Rescana, Help Net Security and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.